Department of Psychology, University of British Columbia, Vancouver, BC, V6T 1Z4, Canada.
Biol Psychiatry. 2010 Apr 1;67(7):649-56. doi: 10.1016/j.biopsych.2009.11.030. Epub 2010 Feb 16.
Stress can increase impulsivity and has a negative impact on psychiatric outcome. Norepinephrine is heavily implicated in responses to stress, and the alpha(2) antagonist yohimbine is used clinically to study this aspect of the stress response. Yohimbine induces mild anxiety and increases impulsivity in healthy volunteers but has more detrimental effects in some psychiatric populations, triggering mania in bipolar patients and drug craving in substance-dependent individuals. Understanding the mechanism by which yohimbine affects brain function could provide insight into the heightened reaction to stress in these patients.
Yohimbine's effects were assessed in rats using the five-choice serial reaction time test of attention and impulse control. We then examined whether yohimbine altered activity of cyclic adenosine monophosphate response element binding (CREB) protein-a transcription factor implicated in the stress response-in brain areas that regulate impulsivity. The behavioral consequences of any changes in CREB activity were subsequently assessed using viral-mediated gene transfer to regionally overexpress CREB or the dominant negative antagonist mCREB.
Yohimbine increased impulsive responding in rats and selectively increased CREB phosphorylation within the orbitofrontal cortex but not medial prefrontal cortex or nucleus accumbens. Overexpressing mCREB within the orbitofrontal cortex blocked yohimbine's effects on impulsivity, whereas overexpressing CREB in this region increased impulsive responding and potentiated the proimpulsive actions of yohimbine.
These data suggest a novel molecular mechanism contributing to impulsivity that may be sensitive to stress. Such findings may improve our understanding of the neurobiological pathways linking the response to stress and impulsivity in both healthy and psychiatric populations.
压力会增加冲动性,并对精神科结果产生负面影响。去甲肾上腺素在应对压力的反应中起着重要作用,而α(2)拮抗剂育亨宾临床上用于研究应激反应的这一方面。育亨宾在健康志愿者中引起轻度焦虑和冲动性增加,但在一些精神科人群中具有更不利的影响,在双相情感障碍患者中引发躁狂,在药物依赖个体中引发药物渴求。了解育亨宾影响大脑功能的机制可以深入了解这些患者对压力的反应增强。
我们使用注意力和冲动控制的五选择连续反应时间测试评估了育亨宾对大鼠的影响。然后,我们研究了育亨宾是否改变了调节冲动性的大脑区域中环磷酸腺苷反应元件结合蛋白(CREB)的活性-一种与应激反应有关的转录因子。随后使用病毒介导的基因转移来区域过表达 CREB 或显性负效拮抗剂 mCREB,评估 CREB 活性任何变化的行为后果。
育亨宾增加了大鼠的冲动反应,并选择性地增加了眶额皮质内的 CREB 磷酸化,但没有增加内侧前额叶皮质或伏隔核内的 CREB 磷酸化。在眶额皮质内过表达 mCREB 阻断了育亨宾对冲动性的影响,而在该区域过表达 CREB 则增加了冲动性反应,并增强了育亨宾的促冲动作用。
这些数据表明,一种新的分子机制可能有助于冲动性,并且可能对压力敏感。这些发现可能会提高我们对将应激反应和冲动性联系起来的神经生物学途径的理解,无论是在健康人群还是精神科人群中。